US FDA lifts partial clinical hold on Rezolute's low blood sugar treatment (updated)
09/09/2024 13:08
(Adds shares in paragraph 1, details in paragraphs 2-4)
Sept 9 (Reuters) - Rezolute Inc RZLT.O said on Monday
the U.S. Food and Drug Administration has removed the partial
clinical hold on its late-stage study testing its treatment for
low blood sugar, sending its share up 11% at $4.83 in premarket
trading.
The treatment, ersodetug, is currently being tested on
participants with congenital hyperinsulinism, a genetic disorder
that causes low blood sugar.
Rezolute anticipates potential U.S. enrollment for the study
to begin in early 2025, and expects to announce results in the
second half of 2025.
The study is enrolling up to 56 participants in more than a
dozen countries, with eligibility ranging from three months to
45 years of age, the company said.
(Reporting by Sneha S K in Bengaluru; Editing by Vijay
Kishore)
((Sneha.SK@thomsonreuters.com;))